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Abstract 
Epitopes involved in protein-protein and protein-nucleic acid interactions provide ideal 
starting points for rational structure-based inhibitor design. The design and optimization of 
epitope mimetics is now emerging as an innovative new approach in drug discovery. 
Although often derided as unsuitable for drug development, we provide examples to show 
how peptidomimetics can provide a new generation of drug candidates to tackle some of the 
most challenging targets in pharmaceutical research, and address some of the most pressing 
current threats to human health. 
 
Introduction 
The design of protein epitope mimetics is now recognized as a promising 
structure/mechanism-based approach for the discovery of protein-protein and protein-nucleic 
acid interaction (PPI and PNI) inhibitors. Molecular recognition involving proteins is often 
mediated by surface exposed secondary structure motifs such as ß-hairpins and α-helices. 
Interest in the development and application of new technologies to mimic such epitopes in 
smaller semi-rigid molecules is growing rapidly. For example, ß-hairpin motifs can be 
mimicked in smaller conformationally constrained macrocyclic molecules [1,2]. Such 
macrocycles are typically constructed from building blocks that can be linked together using 
robust and efficient synthetic methods. By exchanging building blocks, the mimetic 
structures can be varied and their properties optimized using parallel synthetic chemistry. 
This design and optimization process opens an area of molecular space to drug discovery, 
which remains difficult to explore rationally. Protein epitope mimetics are now emerging as 
priveleged ideal scaffolds for addressing some of the most challenging targets in drug 
discovery, namely, protein-protein and protein-nucleic acid interactions. 
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ß-Hairpin mimetic design 
ß-Hairpin motifs in naturally occurring peptides and proteins possess a remarkable degree of 
structural diversity. The diversity can arise due to variations in the loop size, variations in the 
hairpin register, variations in the occurrence of ß-bulges within the ß-strands, and of course 
due to variations in sequence. It is important to note how the register of a ß-hairpin defines 
which pairs of cross-strand amino acids occupy hydrogen-bonding (HB), rather than non-
hydrogen-bonding (NHB), positions. This in turn determines which amino acid side chains 
are displayed on the same face of the hairpin (Figure-1A). ß-Hairpin loops are prominent in 
the antigen-binding sites of antibodies and the ligand binding sites of many cytokine 
receptors and polypeptide growth factors, as well as in many integrins and viral proteins, in a 
wide variety of smaller host-defence peptides such as defensins, venom toxins such as ω-
conotoxin and three-finger snake toxins, in cyclotides, and in Bowman-Birk and related 
proteinase inhibitors, to name but a few. 
 One method to mimic a ß-hairpin motif is to constrain a linear peptide using a 
disulfide bridge. This approach has been valuable in phage-display technology to select 
peptide loop structures that bind to specific protein targets [3]. A disulfide bridge, however, 
has disadvantages, because it can be cleaved in-vivo by reaction with a free thiol group, and 
the disulfide link has many degrees of rotational freedom, which in the absence of other 
stabilizing interactions [4], can make it difficult to stabilize discrete hairpin conformations. ß-
Hairpin conformations have been successfully stabilized in linear peptides by exploiting 
tryptophan zipper motifs (π−π-stacking interactions between cross-strand tryptophans at non-
hydrogen-bonding positions) [5-7]. The residues in the turn region have a strong influence 
upon ß-hairpin stability in linear peptides, with turns formed by Asn-Gly, D-Pro-Gly, Aib-
Gly and Aib-D-Pro being strong promoters of ß-hairpin formation [8,9], due to their 
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propensity to form type-I' or -II' turns. These turn types match the preferred right-handed 
twist of a hairpin. Other building blocks have been incorporated into turn regions and into the 
ß-strand regions, including for example, the 1,2-dihydro-3(6H)-pyridinyl unit that favors 
extended conformations [10]. Recently, a novel hairpin-capping motif has been described, 
which appears to overcome the problem of fraying at the ends of the ß-strands in hairpin 
motifs in linear peptides [11]. The capping motif comprises synergistic stacking and 
hydrogen-bonding interactions between an N-terminal alkanoyl-Trp and a C-terminal -
TrpThrGly- motif, which effectively tie together the ß-strands as long as the Trp residues are 
at terminal non-hydrogen-bonding positions. 
 Stable ß-hairpin scaffolds can also be achieved by linking together the N- and C-
termini, to produce macrocyclic hairpin structures. Nature has also exploited this strategy, as 
evidenced by macrocyclic natural products such as gramicidin S, which has a hairpin 
structure with two D-Phe-L-Pro units marking the turn regions. An interesting dependency of 
ß-sheet periodicity on peptide length was noted in gramicidin S homologs containing 6, 8, 10, 
12, 14 and 16 residues. When the turn positions are defined at each end of the macrocycle by 
D-Phe-Pro, a regular hairpin structure is only seen when the connecting strands contain in 
total (4n+2) amino acids (where n = an integer) [12]. Other approaches to macrocycles with 
stable parallel ß-sheet scaffolds have also been described recently [13,14]. 
 An alternative approach to mimic ß-hairpin structures in naturally occurring peptides 
and proteins, is to transplant the hairpin loop of interest onto an appropriate (semi)-rigid 
template (Figure-1B), or Protein Epitope Mimetic (PEM) technology [1,2]. Most success has 
been reported using the dipeptide fragment D-Pro-L-Pro as a template. This dipeptide 
fragment adopts a rigid type-II' ß-turn, which is ideal to initiate anti-parallel strands held 
together by registered cross-strand hydrogen bonds. Upon transplanting the loop from the 
protein of interest, the cross-strand residue pair directly attached to the D-Pro-L-Pro template 
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will then become a HB pair. In this way, accurate structural mimetics have been produced of 
CDR loops found in antibodies [15], of a ß-hairpin loop in Tat bound to HIV-1 TAR-RNA 
[16-19], of protease inhibitors related to the Bowman-Birk family [20], and of cationic host-
defence peptides related to protegrin-I [21-24] and polyphemusin [25]. It is also noteworthy, 
that hairpin loop mimetics with quite different sizes may be designed in this way. In one case, 
a 13-residue disulfide cross-linked loop taken from a phage display peptide that binds a 
human antibody Fc fragment [26] was transplanted onto a D-Pro-L-Pro template [27]. The 
resulting 13-mer loop was shown to adopt a well-defined ß-hairpin structure, which includes 
a bulge in the second strand close to the turn region, with the unusual result that side-chains 
of two adjacent residues point to the same side of the hairpin. 
 
Using a hairpin to mimic an α-helix 
 Interest in hairpin mimetics is enhanced further by the realization that a hairpin 
scaffold can be exploited to mimic naturally occurring α-helical epitopes. Thus, the distance 
between the Cα atoms of two residues i and i+2 along one strand of a hairpin is very close to 
that between the Cα atoms of two residues i and i+4 on one face of an α-helix (Figure-2). 
Using this information it was possible to design a ß-hairpin to mimic the pharmacophore 
within a helical peptide derived from p53, which is involved in binding to its interacting 
protein HDM2 [28,29]. Template-bound ß-hairpin mimetics were found that indeed bind with 
nanomolar affinity to HDM2. A crystal structure of one mimetic bound to HDM2 confirmed 
that the hairpin scaffold presents three side chains along the first strand of the hairpin for 
binding to HDM2, just like the corresponding three residues situated on one face of the 
helical p53. In addition, residues in the second ß-strand of the mimetic make additional 
favorable contacts with HDM2, which are not seen in the p53-HDM2 complex. Other 
examples of hairpin mimicry of helical epitopes have been reported more recently, based on 
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the interactions of Rev protein to RRE-RNA and of a helical epitope in the chemokine 
receptor CCR5 that binds to the HIV-1 glycoprotein gp120 [30,31]. These examples suggest 
that the hairpin scaffold might be widely applicable in the design of helical epitope mimetics. 
 
Hairpin mimetics in drug discovery 
Until recently, it would have been quite contentious to suggest that peptidomimetics should 
be considered as drug candidates. Afterall, they typically have molecular weights >500, 
possess a plethora of potential hydrogen bonding sites (i.e. they disobey the Lipinski rules 
[32]), are prone to be rapidly degraded in-vivo, and would in any case never cross a cell 
membrane. On the other hand, the genomic and proteomic revolutions continue to provide us 
with an ever-increasing number of mechanistic insights into biological signalling pathways, 
and potential targets for inhibition using small molecules. Unfortunately, many of the genes 
and gene products that are often most attractive from a biological perspective for targeting 
using small molecules are also often the least tractable from the perspective of small drug-
like molecules. Such targets typically include proteins that participate in PPIs or PNIs, which 
are often called "undruggable" within major pharmaceutical companies [33,34]. The 
difficulty in addressing "undruggable" targets using small drug-like molecules [35], however, 
provides a powerful motivation to explore new regions of molecular space to overcome this 
problem. The ß-hairpin mimetics described above are positioned within a relatively 
unexplored region of molecular space, between that of traditional drug-like molecules and the 
much larger 'biologics', such as antibodies. Moreoever, recent progress suggests that many of 
the perceived problems associated with peptidomimetics (proteolytic stability, membrane 
permeability, toxicity, potency) might not be insurmountable for the goal of turning a 
peptidomimetic lead into a successful drug. 
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 In the case of the template-bound ß-hairpin mimetics (PEM molecules), an important 
technology in the optimization of drug-like properties emerges from the field of 
combinatorial chemistry. These macrocyclic PEM molecules are typically constructed from 
building blocks that can be linked together using robust and efficient solid-phase synthesis 
methods. By exchanging building blocks, the mimetic structures can be quickly varied and 
their properties optimized, in an efficient combinatorial fashion, using parallel synthetic 
chemistry [36]. The ease with which PEM analogues can be produced in this way, contrasts 
with the difficulties that often exist in generating analogues of complex natural products. As 
illustrated in Figure-3, the variables for creating combinatorial libraries include the size of the 
ß-hairpin loop, the types of amino acid building blocks, as well as the template. The 
proteinogenic α-amino acids often make convenient starting points for mimetic design, but 
may be exchanged for any of a large number of known non-proteinogenic amino acids, or 
unrelated building bocks [22]. This provides great scope for optimizing drug-like properties 
(ADMET), as well as target affinity and specificity, within a lead series. Some recent 
examples that have led to clinical drug candidates are discussed below. 
 
PEM drug candidates 
1.  Serine protease inhibitors based on the Bowman-Birk motif 
The reactive site loop of the Bowman-Birk (BB) family of serine protease inhibitors 
comprises a ß-hairpin loop, and represents an interesting starting point for the design of PEM 
serine protease inhibitors. One of the smallest members of the BB family was isolated from 
sunflower seeds, and a crystal structure of the inhibitor bound to the active site of trypsin was 
taken as a starting point for PEM design [20].  Initially, mimetics were designed by 
transferring 11 or 7 residues from the BB reactive loop onto a D-Pro-L-Pro template. NMR 
studies on the resulting mimetics revealed a well-defined ß-hairpin conformation in aqueous 
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solution, essentially identical to that seen in the natural peptide (Figure-4A). Enzymatic 
assays showed that the mimetics inhibit bovine trypsin with low to mid nanomolar Ki values, 
and an alanine scan confirmed the energetically important role of a Lys side chain, which 
occupies the P1 position. This PEM scaffold was recently used to generate a diverse library 
of serine protease inhibitors from which new, potent and selective inhibitors were discovered 
targeting pharmaceutically important serine proteases, such as cathepsin G, human neutrophil 
elastase (HNE), and tryptase, implicated in chronic obstructive pulmonary disease (COPD) 
and asthma [2]. 
 For example, POL6014 is a fully reversible, competitive and potent HNE inhibitor 
(Ki 1.4 nM) with potential as an inhaled therapeutic for the treatment of lung diseases such as 
COPD, cystic fibrosis (CF) and acute lung injury (ALI). COPD is one of the leading causes 
of death and disability worldwide and there is an important medical need for new therapies 
that prevent disease progression or reduce mortality [37,38]. HNE plays an important role 
both in mucus hypersecretion and lung tissue destruction leading to emphysema [39]. A 
potential advantage of the PEM scaffold is that it allows formulation as an aerosol with a 
mass median aerodynamic diameter (MMAD) of 2.6 mm at the highest nebulized dose, 
compatible with deep lung (alveoli) respirability. In recent studies, POL6014 demonstrated a 
very good pharmacokinetic profile for an inhaled application in the lung. The pK is 
characterized by an excellent lung retention and a >100-fold ratio of concentrations in the 
airways compared to the plasma in two different species and with two different local routes 
of administration, thus minimizing potential side effects associated with a high systemic 
exposure. In addition, POL6014 was shown to significantly inhibit HNE-induced acute lung 
injury in mice. POL6014 was recently successfully evaluated in additional animal efficacy 
models, and preliminary toxicology studies in mice and monkey showed a good safety 
profile. 
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2. Mimetics of protegrin I as novel antibacterials 
  The large family of cationic host-defence peptides plays an important role in anti-
infective defence mechanisms in many organisms [40]. They are typically short cationic 
peptides of 10-50 residues, with a net positive charge of +2 to +10. They often share 
amphipathic properties, but differ widely in sequence and secondary structures. These 
peptides not only possess antimicrobial activity, but also often have broad functions in the 
immune systems of their hosts, where they act at the interface of the innate and adaptive 
immune responses, and participate in multiple aspects of immunity, inflammation, wound 
repair and in maintaining homeostasis [41,42]. Not surprisingly, this family of peptides has 
already attracted great interest as a potential source of new antibiotics. Of special interest, 
however, are cases where novel mechanisms of antimicrobial activity can be demonstrated. 
In one example, the cationic antimicrobial peptide protegrin-I (PG-I) was taken as a starting 
point for ß-hairpin mimetic design [22]. PG-I adopts a ß-hairpin secondary structure in 
solution, which is stabilized by two cross-strand disulfide bridges. This ß-hairpin is also 
amphipathic, so the molecule is attracted through its positive charge to the negatively charged 
surface of bacteria, where it can then insert into and lyse the cell membrane. PG-I displays 
broad spectrum antimicrobial activity, but in the micromolar range. A family of PEM 
molecules modeled on PG-I was reported recently, that show potent antimicrobial activity, 
including the lead compound L27-11 (Figure-4B) which is active in the nanomolar range, but 
only against Pseudomonas species and in particular the important human pathogen 
Pseudomonas aeruginosa [21]. The PEM molecules have a hairpin structure stabilized now 
by a D-Pro-L-Pro template, are positively charged and so are attracted to the surface of 
bacterial cells, but are not amphipathic and so do not lyse cells. Rather, they are able to target 
an essential bacterial ß-barrel outer membrane (OM) protein called LptD. No other peptides 
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or natural products are currently known that interact with LptD (also called Imp or OstA). 
This OM protein forms a complex with a lipoprotein called LptE in the OM, and both are 
essential for the assembly of the lipopolysaccharide (LPS) layer in the outer leaflet of the OM 
in many Gram-negative bacteria [43-45]. When the function of LptD is blocked, OM 
biogenesis is disrupted. The discovery of L27-11 involved an iterative process in which an 
initial hit was optimized by PEM library synthesis and screening for improved antimicrobial 
activity. The optimal hit from each library was used as a starting point for the synthesis and 
testing of variations in a subsequent library. The same procedure was then followed to 
optimize the drug-like properties of L27-11. This included optimization of the plasma 
stability, target selectivity, and toxicology. This process resulted in the compound POL7001 
and then a clinical lead candidate POL7080 [21]. The safety of mimetic POL7080 is now 
being tested in healthy humans in a phase I clinical study, but it is clear already that it 
represents the first in a new class of antibiotics active against Gram-negative bacteria. 
 
3. Inhibitors of CXCR4 
CXCR4 belongs to the class-A family of G-protein coupled receptors (GPCRs) and is 
used as a co-receptor for CD4-dependent HIV infection of human T-cells. Because CXCR4 is 
expressed on the surface of the majority of hematopoietic stem cells (HSCs) and interacts 
with its natural ligand SDF-1 in the bone marrow (BM), it also plays an important role in 
hematopoietic stem cell mobilization from the BM to peripheral blood. CXCR4 antagonists 
are promising new therapeutics for the efficient mobilization and harvesting of peripheral 
blood HSCs by disruption of the SDF-1/CXCR4 interaction [46], in cancer therapy as anti-
metastatic agents [47], as well as in inflammation and tissue repair [48]. 
 Polyphemusin II is an 18-amino acid peptide isolated from the American horseshoe 
crab (Limulus polyphemus) that inhibits CXCR4 and adopts a β-hairpin structure in solution. 
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Based on this structure, several PEM molecules were designed and optimized in biological 
assays. This led to highly potent and selective CXCR4 antagonist such as POL3026, 
POL5551 and POL6326 [2,25]. POL6326 has now successfully moved into a phase II 
clinical trial for autologous stem cell transplantation in newly diagnosed multiple myeloma 
patients. Interim results from this study show that POL6326 is safe, well tolerated and 
efficient in mobilizing HSCs. Grafts mobilized with POL6326 also show favourable 
engraftment with re-establishment of the patients' hematopoetic system. In addition, 
preliminary results show that POL6326 treatment mobilizes very limited or no tumor cells in 
the leukapheresis product. These positive findings warrant further clinical development of 
POL6326. In a different application, POL5551 significantly inhibited neointimal 
accumulation of CXCR4+ smooth muscle cells (SMCs) after vascular injury in a wire-
induced restenosis mouse model [49]. In addition, a local lung administration of POL5551 
significantly protects against inflammation and reduces lung hyper-responsiveness in an 
allergic murine model of asthma. These recent examples show the great therapeutic potential 
of PEM CXCR4 antagonists. 
 Recently, an X-ray structure revealed how a very closely related ß-hairpin-shaped 
peptide binds to an engineered form of CXCR4  (Figure-4C) [50]. The ß-hairpin occupies a 
binding site on CXCR4 formed by residues in the inward-facing protruding walls of the 
seven transmembrane helical bundle, several extracellular loops, and the N-terminal segment.  
A network of polar, hydrogen-bonding and hydrophobic contacts between the ligand and the 
receptor are responsible for the specific high affinity interaction. The close structural 
similarity between this bound ligand and POL3026, suggets that the macrocyclic ß-hairpin 
mimetic will interact with CXCR4 in an essentially identical manner. 
 
Conclusions 
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Protein epitope mimetic technologies provide a rational approach for the design of inhibitors 
of some of the most challenging targets in pharmaceutical research, namely, protein-protein 
and protein-nucleic acid interactions. So far most effort has been on epitopes that are 
localized in discrete secondary structures on the surface of proteins, such as in α-helices and 
ß-hairpins. The macrocyclic PEM molecules highlighted in this article have the added 
advantage that they can be adapted to mimic α-helical as well as hairpin epitopes. 
Furthermore, their production by efficient parallel synthesis methods allows the rapid 
synthesis and screening of libraries, and this in turn allows optimization of not only target 
affinity and selectivity, but also other drug-like (ADMET) properties, such as stability, 
pharmacology and toxicology. This has now been demonstrated in two series of ß-hairpin 
mimetics that have each been tested in the clinic, where they have demonstrated excellent 
safety profiles. The two families of ß-hairpin mimetics represented by POL6326 and 
POL7080 both target protein receptors that are located in the cell membrane. This has the 
added advantage that it is not a priori necessary to endow the mimetics with the property of 
cell permeability, which in turn is likely to pose fewer problems in toxicology. In cases where 
cell permeability is required, in order to address intracellular targets, methods will be 
required to engineer the peptide backbone, and perhaps also side chain groups, to allow 
passage of the mimetics across the cell membrane, by either passive diffusion or by promoted 
uptake. Due to their favorable physicochemical properties hairpin mimetics are also ideally 
suited for systemic applications (for example, by i.v., s.c., or as slow release subcutaneous 
implants), or alternatively for inhaled therapies (in the form of aerosols, and dry powder 
formulations) in the area of lung diseases. The two ß-hairpin mimetics that have so far 
successfully entered human clinical trials (POL6326, phase II; POL7080, phase I) represent 
important milestones and highlight the clinical relevance of the ß-hairpin PEM approach in 
drug discovey. 
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Figure-1. A, Ribbon representations of two hairpin loops with different hairpin registers. The 
blue dotted lines represent residues at a cross-strand hydrogen-bonding (HB) position. B, In 
template bound hairpin mimetics the hydrogen bonding register is fixed through covalent 
linkage to the template (D-Pro-L-Pro, shown in purple, right). The two loop residues directly 
linked to the template must occupy a HB position.. 
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Figure-2. Superimposition of a ß-hairpin mimetic (blue, with D-Pro-L-Pro template) and a 
helical epitope in p53 (pink) to illustrate how the hairpin scaffold can present three side 
chains equivalent to those on one face of an α-helix (see [28,29]). 
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Figure-3. The synthesis of template-bound ß-hairpin mimetics proceeds efficiently in a 
parallel combinatorial format, which allows the rapid synthesis and screening of libraries, and 
thereby the rapid optimization of properties. 
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Figure-4. A, A template-bound ß-hairpin mimetic (NMR structure shown in green/blue/red) 
superimposed upon the active-site loop of a Bowman-Birk-family protease inhibitor. B, the 
template-bound ß-hairpin antibiotic L27-11 that binds to the outer membrane protein LptD. 
C, A hairpin-shaped peptide (in green) bound to an engineered CXCR4 (PDB file 3OE0). 
 
 
 
 
 
 
 
 
